Loading...
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
Giuliano, M Giordano, A Jackson, S Hess, KR De Giorgi, U Mego, M Handy, BC Ueno, NT Alvarez, RH De Laurentiis, M
Giuliano, M
Giordano, A
Jackson, S
Hess, KR
De Giorgi, U
Mego, M
Handy, BC
Ueno, NT
Alvarez, RH
De Laurentiis, M
Citations
Altmetric:
Genre
Journal Article
Date
2011-06-15
Advisor
Committee member
Group
Department
Subject
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Bevacizumab
Biomarkers, Tumor
Breast Neoplasms
Cell Line, Tumor
Cells, Cultured
Disease Progression
ErbB Receptors
Female
Humans
Lapatinib
Middle Aged
Neoplastic Cells, Circulating
Predictive Value of Tests
Prognosis
Quinazolines
Trastuzumab
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Bevacizumab
Biomarkers, Tumor
Breast Neoplasms
Cell Line, Tumor
Cells, Cultured
Disease Progression
ErbB Receptors
Female
Humans
Lapatinib
Middle Aged
Neoplastic Cells, Circulating
Predictive Value of Tests
Prognosis
Quinazolines
Trastuzumab
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.1186/bcr2907
Abstract
Introduction: Circulating tumor cells (CTCs) represent an independent predictor of outcome in patients with metastatic breast cancer (MBC). We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients.Methods: We retrospectively evaluated 235 newly diagnosed MBC patients, treated at the University of Texas MD Anderson Cancer Center. All patients had a baseline CTC assessment performed with CellSearch ®. Progression-free survival and overall survival were compared with the log-rank test between groups, according to CTC count (< 5 vs. ≥ 5) and type of systemic therapy. We further explored the predictive value of baseline CTCs in patients receiving different treatments.Results: At a median follow-up of 18 months, the CTC count was confirmed to be a robust prognostic marker in the overall population (median progression-free survival 12.0 and 7.0 months for patients with CTC < 5 and ≥ 5, respectively; P < 0.001). Conversely, in patients with human epidermal growth factor receptor-2-overexpressed/amplified tumors receiving trastuzumab or lapatinib, the baseline CTC count was not prognostic (median progression-free survival 14.5 months for patients with CTC < 5 and 16.1 months for those with CTC ≥ 5; P = 0.947). Furthermore, in patients with human epidermal growth factor receptor-2 normal tumors, a baseline CTC count ≥ 5 identified subjects who derived benefit from more aggressive treatments, including combination chemotherapy and chemotherapy plus bevacizumab.Conclusions: This analysis suggests that the prognostic information provided by CTC count may be useful in patient stratifications and therapeutic selection, particularly in the group with positive CTCs, in which various therapeutic choices may procure differential palliative benefit. © 2011 Giuliano et al.; licensee BioMed Central Ltd.
Description
Citation
Citation to related work
Springer Science and Business Media LLC
Has part
Breast Cancer Research
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu